 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > Lynx Therapeutics, Inc.
 |
Lynx Therapeutics, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Lynx reports wider Q2 loss Jul 18 2001 06:00 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
The human genome may have been mapped, but Lynx Therapeutics knows there's still a lot of genomics work to be done. The firm creates DNA cloning and analysis technologies that it hopes will enhance gene discovery, gene expression, genome mapping, characterization of gene functions, and the study of plant and animal genes. Working with such partners as BASF, Oxagen, and Aventis CropScience, Lynx discovers single nucleotide polymorphisms (SNPs) related to such diseases as diabetes, as well as those found in plants; finds genes related to central nervous system disorders and validates drug targets (through its BASF-LYNX Bioscience joint venture with BASF); and conducts other genomics studies.
COMPETITION |
 |
APBiotech Inc (dossier)
Affymetrix, Inc. (AFFX)
Applied Biosystems Group (ABI)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 12.60
1-Yr. Sales Growth: (2.3)%
Employees: 156
Revenue per employee: $80,769.23
KEY PEOPLE |
 |
Norman J. W. Russell
CEO
Edward C. Albini
CFO
CONTACT INFO |
 |
25861 Industrial Blvd.
Hayward, CA 94545
US
Phone: 510-670-9300
Fax: 510-670-9302
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |